Literature DB >> 24662435

Nephrotoxic effects of designer drugs: synthetic is not better!

Randy L Luciano1, Mark A Perazella1.   

Abstract

Designer drugs are synthetic, psychoactive substances with similar structures and activity to existing scheduled drugs or controlled chemical compounds. The use of these drugs is not generally considered illegal and they cannot be detected using standard toxicology tests--essentially they are considered to be 'legal highs'. Over the past several years, increasing numbers of designer drugs have become available. These drugs are classified as amphetamine derivatives, phenylpiperazine derivatives, synthetic cathinones, synthetic cannabinoids, phencyclidine derivatives and synthetic opioids. Although euphoria is the desired effect, neuropsychiatric and cardiac manifestations are frequently observed in individuals using these drugs at high doses or using drugs that are contaminated with other substances. Some designer drugs are also associated with adverse renal effects, including acute kidney injury from pigment nephropathy, acute tubular necrosis, obstructive nephropathy and hyponatraemia. The misuse of these drugs should be recognized and clinicians made aware of the potential for acute nephrotoxicity as the health burden of these compounds increases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662435     DOI: 10.1038/nrneph.2014.44

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  105 in total

Review 1.  Piperazine compounds as drugs of abuse.

Authors:  M D Arbo; M L Bastos; H F Carmo
Journal:  Drug Alcohol Depend       Date:  2011-11-08       Impact factor: 4.492

2.  Myocardial infarction associated with use of the synthetic cannabinoid K2.

Authors:  Arshid Mir; Adebisi Obafemi; Amy Young; Colin Kane
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

3.  Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use.

Authors:  I Ajaelo; K Koenig; E Snoey
Journal:  Acad Emerg Med       Date:  1998-08       Impact factor: 3.451

Review 4.  Drug abuse: newly-emerging drugs and trends.

Authors:  Gregory G Davis
Journal:  Clin Lab Med       Date:  2012-06-27       Impact factor: 1.935

5.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial.

Authors:  S J Lester; M Baggott; S Welm; N B Schiller; R T Jones; E Foster; J Mendelson
Journal:  Ann Intern Med       Date:  2000-12-19       Impact factor: 25.391

7.  Ecstasy induced hepatitis mimicking viral hepatitis.

Authors:  R S Dykhuizen; P W Brunt; P Atkinson; J G Simpson; C C Smith
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

8.  Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion.

Authors:  T K Hartung; E Schofield; A I Short; M J A Parr; J A Henry
Journal:  QJM       Date:  2002-07

9.  "Ecstasy" and sudden cardiac death.

Authors:  R V Suarez; R Riemersma
Journal:  Am J Forensic Med Pathol       Date:  1988-12       Impact factor: 0.921

10.  College students and use of K2: an emerging drug of abuse in young persons.

Authors:  Xingdi Hu; Brian A Primack; Tracey E Barnett; Robert L Cook
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-07-11
View more
  9 in total

Review 1.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

2.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

4.  Rhabdomyolysis observed at forensic autopsy: a series of 52 cases.

Authors:  Hsuan-Yun Hu; Shyh-Yuh Wei; Chih-Hsin Pan
Journal:  Forensic Sci Med Pathol       Date:  2018-07-28       Impact factor: 2.007

5.  Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Authors:  Lauren C Smith; Paul T Bremer; Candy S Hwang; Bin Zhou; Beverly Ellis; Mark S Hixon; Kim D Janda
Journal:  J Am Chem Soc       Date:  2019-06-25       Impact factor: 15.419

Review 6.  Systematic review of nephrotoxicity of drugs of abuse, 2005-2016.

Authors:  Kanaan Mansoor; Murad Kheetan; Saba Shahnawaz; Anna P Shapiro; Eva Patton-Tackett; Larry Dial; Gary Rankin; Prasanna Santhanam; Antonios H Tzamaloukas; Tibor Nadasdy; Joseph I Shapiro; Zeid J Khitan
Journal:  BMC Nephrol       Date:  2017-12-29       Impact factor: 2.388

7.  Cat on a hot tin roof (a nephrology zebra).

Authors:  Samuel Wacrenier; Jean Philippe Coindre; Sophie Blanchi; Giorgina Barbara Piccoli
Journal:  J Nephrol       Date:  2021-04-23       Impact factor: 3.902

Review 8.  Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.

Authors:  Stefano D'Errico; Martina Zanon; Davide Radaelli; Monica Concato; Martina Padovano; Matteo Scopetti; Paola Frati; Vittorio Fineschi
Journal:  Biomedicines       Date:  2022-08-10

Review 9.  The nephrologist's guide to cannabis and cannabinoids.

Authors:  Joshua L Rein
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.